Literature DB >> 12134945

Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?

Fuxing Tang1, Kazutoshi Horie, Ronald T Borchardt.   

Abstract

PURPOSE: To investigate whether Madin-Darby canine kidney cells transfected with the human MDR1 gene (MDCK-MDR1) are a good model of the human intestinal mucosa.
METHODS: P-glycoprotein (P-gp) expression in Caco-2 cells was compared with P-gp expression in MDCK wild- type (MDCK-WT) and MDCK-MDR1 cells using Western blotting methods. The polarized efflux activities of P-gp(s) in MDCK-MDRI cells, MDCK-WT cells, and Caco-2 cells were compared using digoxin as a substrate. Apparent Michaelis-Menten constants (K(M),Vmax) for the efflux of vinblastine in these three cell lines were determined. Apparent inhibition constants (K(I)) of known substrates/inhibitors of P-gp were determined by measuring their effects on the efflux of digoxin in Caco-2 or MDCK-MDR1 cell monolayers.
RESULTS: MDCK-MDR1 cells expressed higher levels of P-gp compared to Caco-2 and MDCK-WT cells, as estimated by Western blots. Two isoforms of P-gp were expressed in Caco-2 and MDCK cells migrating with molecular weights of 150 kDa and 170 kDa. In MDCK-MDR1 cells, the 150 kDa isoforms appeared to be overexpressed. The MDCK-MDR1 cells exhibited higher polarized efflux of [3H]-digoxin than did Caco-2 and MDCK-WT cells. K(M) values of vinblastine in Caco-2. MDCK-WT, and MDCK-MDR1 cells were 89.2+/-26.1, 24.5+/-1.1, and 252.8+/-134.7 microM, respectively, whereas Vmax values were 1.77+/-0.22, 0.42+/-0.01, and 2.43+/-0.86 pmolcm(-2)s(-1), respectively. Known P-gp substrates/inhibitors showed, in general, lower K(I) values for inhibition of digoxin efflux in Caco-2 cells than in MDCK-MDR1 cells.
CONCLUSIONS: These data suggest that the MDCK-MDR1 cells overexpress the 150 kDa isoform of P-gp. MDCK-MDR1 cells are a useful model for screening the P-gp substrate activity of drugs and drug candidates. However, the apparent kinetics constants and affinities of substrates determined in the MDCK-MDR1 cell model may be different than the values obtained in Caco-2 cells. These differences in substrate activity could result from differences in the relative expression levels of total P-gp in Caco-2 and MDCK-MDR1 cells and/or differences in the partitioning of substrates into these two cell membrane bilayers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134945     DOI: 10.1023/a:1016140429238

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  49 in total

Review 1.  Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane.

Authors:  J Ferté
Journal:  Eur J Biochem       Date:  2000-01

2.  The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface.

Authors:  R Callaghan; G Berridge; D R Ferry; C F Higgins
Journal:  Biochim Biophys Acta       Date:  1997-09-04

3.  The application of cell culture systems in drug discovery and development.

Authors:  R Borchardt
Journal:  J Drug Target       Date:  1995       Impact factor: 5.121

4.  Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues.

Authors:  C Tanaka; R Kawai; M Rowland
Journal:  Drug Metab Dispos       Date:  2000-05       Impact factor: 3.922

5.  P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels.

Authors:  P Anderle; E Niederer; W Rubas; C Hilgendorf; H Spahn-Langguth; H Wunderli-Allenspach; H P Merkle; P Langguth
Journal:  J Pharm Sci       Date:  1998-06       Impact factor: 3.534

6.  Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells.

Authors:  F J Sharom; X Yu; J W Chu; C A Doige
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

Review 7.  Multidrug-resistance phenotype in Chinese hamster ovary cells.

Authors:  V Ling; N Kartner; T Sudo; L Siminovitch; J R Riordan
Journal:  Cancer Treat Rep       Date:  1983-10

8.  Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.

Authors:  L Z Benet; T Izumi; Y Zhang; J A Silverman; V J Wacher
Journal:  J Control Release       Date:  1999-11-01       Impact factor: 9.776

9.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

Authors:  F Hyafil; C Vergely; P Du Vignaud; T Grand-Perret
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

10.  Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers.

Authors:  K I Hosoya; K J Kim; V H Lee
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

View more
  46 in total

1.  Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter.

Authors:  Kazutoshi Horie; Fuxing Tang; Ronald T Borchardt
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

2.  The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.

Authors:  Thuy Thanh Tran; Aditya Mittal; Tanya Aldinger; Joseph W Polli; Andrew Ayrton; Harma Ellens; Joe Bentz
Journal:  Biophys J       Date:  2004-10-22       Impact factor: 4.033

Review 3.  Pharmacophore-based discovery of ligands for drug transporters.

Authors:  Cheng Chang; Sean Ekins; Praveen Bahadduri; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2006-09-26       Impact factor: 15.470

4.  P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?

Authors:  Praveen V Balimane; Anthony Marino; Saeho Chong
Journal:  AAPS J       Date:  2008-12-11       Impact factor: 4.009

5.  Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination.

Authors:  Donna A Volpe; Salaheldin S Hamed; Lei K Zhang
Journal:  AAPS J       Date:  2013-12-13       Impact factor: 4.009

6.  Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.

Authors:  Konstantin Kuteykin-Teplyakov; Carlos Luna-Tortós; Kamila Ambroziak; Wolfgang Löscher
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

7.  Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.

Authors:  Mitesh Patel; Ye Sheng; Nanda K Mandava; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2014-09-26       Impact factor: 5.875

8.  Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.

Authors:  Nagdeep Giri; Sagar Agarwal; Naveed Shaik; Guoyu Pan; Ying Chen; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2008-12-04       Impact factor: 3.922

9.  P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents.

Authors:  Fionn E O'Brien; Richard M O'Connor; Gerard Clarke; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Neuropsychopharmacology       Date:  2013-05-14       Impact factor: 7.853

10.  Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models.

Authors:  Yu-hua Li; Hui-chang Bi; Ling Huang; Jing Jin; Guo-ping Zhong; Xu-nian Zhou; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2013-12-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.